10/685,172

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	175	cyanine$1 same receptor	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2006/09/12 11:36
L2	30	l1 and bombesin	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2006/09/12 10:17
L3	8	l1 same bombesin	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2006/09/12 10:18
L4	5	l3 and azide	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2006/09/12 10:18
L5	4	cyanine$1 same receptor same azide	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2006/09/12 11:42
L6	2	("3887379").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/09/12 11:45
L7	2	("6004536").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/09/12 11:45

10/685,172

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

[redacted]

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1         Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2         "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27  New STN AnaVist pricing effective March 1, 2006
 NEWS  4  MAY 10  CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  5  MAY 11  KOREAPAT updates resume
 NEWS  6  MAY 19  Derwent World Patents Index to be reloaded and enhanced
 NEWS  7  MAY 30  IPC 8 Rolled-up Core codes added to CA/CAplus and
                  USPATFULL/USPAT2
 NEWS  8  MAY 30  The F-Term thesaurus is now available in CA/CAplus
 NEWS  9  JUN 02  The first reclassification of IPC codes now complete in
                  INPADOC
 NEWS 10  JUN 26  TULSA/TULSA2 reloaded and enhanced with new search and
                  and display fields
 NEWS 11  JUN 28  Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 12  JUl 11  CHEMSAFE reloaded and enhanced
 NEWS 13  JUl 14  FSTA enhanced with Japanese patents
 NEWS 14  JUl 19  Coverage of Research Disclosure reinstated in DWPI
 NEWS 15  AUG 09  INSPEC enhanced with 1898-1968 archive
 NEWS 16  AUG 28  ADISCTI Reloaded and Enhanced
 NEWS 17  AUG 30  CA(SM)/CAplus(SM) Austrian patent law changes
 NEWS 18  SEP 11  CA/CAplus enhanced with more pre-1907 records

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:49:10 ON 12 SEP 2006

=> FIL CAPLUS
COST IN U.S. DOLLARS                              SINCE FILE     TOTAL
                                                       ENTRY   SESSION
```

```
FULL ESTIMATED COST                                          0.21        0.21

FILE 'CAPLUS' ENTERED AT 12:49:23 ON 12 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 12 Sep 2006  VOL 145 ISS 12
FILE LAST UPDATED: 11 Sep 2006  (20060911/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s cyanine and conjugate
         15234 CYANINE
          1353 CYANINES
         15631 CYANINE
                 (CYANINE OR CYANINES)
         65955 CONJUGATE
         59021 CONJUGATES
        102414 CONJUGATE
                 (CONJUGATE OR CONJUGATES)
L1         380 CYANINE AND CONJUGATE

=> s l1 and receptor
        666357 RECEPTOR
        611067 RECEPTORS
        792957 RECEPTOR
                 (RECEPTOR OR RECEPTORS)
L2          75 L1 AND RECEPTOR

=> s l2 and (?endotoxin or neurotensin or bombesin or cholesystekinin or steroid or
carbohydrate)
         27322 ?ENDOTOXIN
          4757 NEUROTENSIN
            27 NEUROTENSINS
          4760 NEUROTENSIN
                 (NEUROTENSIN OR NEUROTENSINS)
          4216 BOMBESIN
            22 BOMBESINS
          4221 BOMBESIN
                 (BOMBESIN OR BOMBESINS)
             0 CHOLESYSTEKININ
        110511 STEROID
        112418 STEROIDS
        168571 STEROID
                 (STEROID OR STEROIDS)
        127013 CARBOHYDRATE
        145030 CARBOHYDRATES
        210982 CARBOHYDRATE
```

```
                (CARBOHYDRATE OR CARBOHYDRATES)
L3              21 L2 AND (?ENDOTOXIN OR NEUROTENSIN OR BOMBESIN OR CHOLESYSTEKININ
                   OR STEROID OR CARBOHYDRATE)

=> s l3 and azide
         42034 AZIDE
          8781 AZIDES
         44503 AZIDE
                (AZIDE OR AZIDES)
L4               3 L3 AND AZIDE

=> d l4 ibib abs hitstr tot

L4   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2004:652430  CAPLUS
DOCUMENT NUMBER:         141:179566
TITLE:                   Compounds for dual photodiagnosis and therapy
INVENTOR(S):             Rajagopalan, Raghavan; Achilefu, Samuel I.; Bugaj,
                         Joseph E.; Dorshow, Richard B.; Periasamy, Muthunadar
                         P.
PATENT ASSIGNEE(S):      Mallinckrodt Inc., USA
SOURCE:                  U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S.
                         Ser. No. 898,885.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
     US 2004156783        A1    20040812   US 2003-685172         20031014
     US 2003017164        A1    20030123   US 2001-898885         20010703
     US 2004161430        A1    20040819   US 2004-776840         20040211
     AU 2004282131        A1    20050428   AU 2004-282131         20041007
     CA 2542694           AA    20050428   CA 2004-2542694        20041007
     WO 2005037928        A2    20050428   WO 2004-US32859        20041007
     WO 2005037928        A3    20050616
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     EP 1680472           A2    20060719   EP 2004-794269         20041007
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
PRIORITY APPLN. INFO.:                 US 2001-898885      A2 20010703
                                       US 2003-685172      A  20031014
                                       WO 2004-US32859     W  20041007
AB   The invention discloses compds. and compns. for dual phototherapy and
     combined therapy and diagnosis of tumors and other lesions.  The compds.
     have a Dye that, when photoactivated, operates via Type I and/or Type II
     mechanisms.  Other Dye or azide components may operate by the
     same or different mechanisms.  Selection of particular components in a
     compound, and formulation of the compound(s) in a composition permit different
     activation wavelengths to be used for different therapies.  A targeting
     moiety may be added to the compound or composition so that the Dye locates at a
     particular site, such as a hormone-sensitive tumor, for diagnosis and/or
     treatment.  The compds. and compns. may be incorporated within liposomes.

L4   ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2003:42026  CAPLUS
DOCUMENT NUMBER:          138:78436
TITLE:                    Dye-azide compounds for dual phototherapy
INVENTOR(S):              Rajagopalan, Raghavan; Achilefu, Samuel I.; Bugaj,
                          Joseph E.; Dorshow, Richard B.
PATENT ASSIGNEE(S):       Mallinckrodt Inc., USA
SOURCE:                   PCT Int. Appl., 40 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND    DATE          APPLICATION NO.          DATE
     ---------------     ----    --------      --------------------     --------
     WO 2003003806        A2     20030116      WO 2002-US19187          20020618
     WO 2003003806        A3     20040408
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2003017164        A1     20030123      US 2001-898885           20010703
     CA 2452752           AA     20030116      CA 2002-2452752          20020618
     AU 2002320098        A1     20030121      AU 2002-320098           20020618
     EP 1427712           A2     20040616      EP 2002-749597           20020618
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2005503364        T2     20050203      JP 2003-509836           20020618
     US 2004161430        A1     20040819      US 2004-776840           20040211
PRIORITY APPLN. INFO.:                         US 2001-898885       A   20010703
                                               WO 2002-US19187      W   20020618
OTHER SOURCE(S):         MARPAT 138:78436
AB   The present invention discloses dye-azide derivs. and their
     bioconjugates for dual phototherapy of tumors and other lesions.  The
     compds. of the present invention may contain either a mixture of Type 1
     (direct energy or electron transfer from photosensitizer to cellular
     components) and Type 2 (singlet oxygen-mediated therapeutic action) agents
     or a single entity that integrates both units in the same mols.  The
     compds. are designed to produce both Type 1 and Type 2 phototherapeutic
     effect at once using dual wavelength light source that will produce
     singlet oxygen and nitrene at the lesion of interest.  This is
     accomplished using 3 types of formulation: homogenous mixts. of Type 1 and
     Type 2 agents alone, heterogeneous mixts. of Type 1 and Type 2 agents, or
     a single mol. entity containing both Type 1 and Type 2 functionalities.
     Suggested as single mol. entities are dyes (cyanines,
     porphyrins, phthalocyanines, etc.) conjugated to both organic azides
     and to biomol. targeting agents such as receptor (somatostatin,
     steroid, carbohydrate, etc.)-binding mols.

L4   ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2001:284222  CAPLUS
DOCUMENT NUMBER:          134:307611
TITLE:                    Conjugated polymer tag complexes and their preparation
```

```
                         and use in assays
INVENTOR(S):             Leif, Robert C.; Franson, Richard C.; Vallarino, Lidia
PATENT ASSIGNEE(S):      USA
SOURCE:                  PCT Int. Appl., 104 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
     WO 2001027625        A1    20010419    WO 2000-US27787         20001007
         W:  CA, CH, DE, FI, GB, JP, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
     CA 2387380           AA    20010419    CA 2000-2387380         20001007
     EP 1221052           A1    20020710    EP 2000-968871          20001007
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY
PRIORITY APPLN. INFO.:                      US 1999-158718P     P  19991008
                                            WO 2000-US27787     W  20001007
AB   Processes are described for: (1) the sequential solid phase synthesis of
     polymers with at least one tag, which can be a light emitting and/or
     absorbing mol. species (optical-label), a paramagnetic or radioactive
     label, or a tag that permits the phys. separation of particles including cells.
     When multiple optical-labels are suitably arranged in three-dimensional
     space, the energy transfer from one mol. species to another can be
     maximized and the radiationless loss between members of the same mol.
     species can be minimized; (2) the coupling of these polymers to biol.
     active and/or biol. compatible mols. through peripheral pendant
     substituents having at least one reactive site; and (3) the specific
     cleavage of the coupled polymer from a solid phase support.  The
     tagged-peptide or polymers produced by these processes and their
     conjugates with an analyte-binding species, such as a monoclonal
     antibody or a polynucleotide probe are described.  When functionalized
     europium macrocyclic complexes, as taught in our U.S. patents 5,373,093
     and 5,696,240, are bound to polylysine and other peptides, the emitted
     light increases linearly with the amount of bound macrocyclic complex.
     Similar linearity will also result for multiple luminescent macrocyclic
     complexes of other lanthanide ions, such as samarium, terbium, and
     dysprosium, when they are bound to a polymer or mol.
REFERENCE COUNT:         2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s l1 and azide
         42034 AZIDE
          8781 AZIDES
         44503 AZIDE
                 (AZIDE OR AZIDES)
L5          11 L1 AND AZIDE

=> s l5 not l4
L6             8 L5 NOT L4

=> d l6 ibib abs hitstr tot

L6   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2006:410229  CAPLUS
DOCUMENT NUMBER:         144:451994
TITLE:                   Reactive 1,3'-crosslinked carbocyanines and their
                         bioconjugates
```

```
INVENTOR(S):             Diwu, Zhenjun; Zhang, Jianheng; Tang, Yi; Xiang,
                         Guobing
PATENT ASSIGNEE(S):      Anaspec, Inc., USA
SOURCE:                  PCT Int. Appl., 103 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     WO 2006047452        A2    20060504    WO 2005-US38259        20051021
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
             NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
             SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
             YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     US 2006121503        A1    20060608    US 2005-256581         20051021
PRIORITY APPLN. INFO.:                      US 2004-621789P     P  20041025
GI



* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

AB    Chemical reactive carbocyanine dyes that are intramolecularly crosslinked
      between the 1-position and 3'-position, their bioconjugates and their uses
      are described.  These 1,3'-crosslinked carbocyanines provide bioconjugates
      with higher fluorescence than those of conjugates of spectrally
      similar 1,1'-crosslinked or non-crosslinked dyes.  The invention includes
      derivative compds. having one or more benzo nitrogens.  Dye I was manufactured
by
      reaction of K 2,3,3-trimethylindolinium-5-sulfonate 10 h at 120°
      with 6-bromohexanoic acid in 1,2-dichlorobenzene, reaction of the
      resulting intermediate 1 h at 120° with malonaldehyde
      bis(phenylimine) monochloride in the presence of Ac2O and HOAc, reaction
      of the 2nd intermediate 30 min with indole derivative II in the presence of
      addition Ac2O and C5H5N at 120°, reaction of the 3rd intermediate with
      O-(N-succinimdyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 1 h in
      DMF in the presence of Et3N, and reaction of the resulting disuccinimyl
      ester with lysine N-(5-carboxypentyl)amide overnight in water in the
      presence of Na2CO3.

L6    ANSWER 2 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2005:611990  CAPLUS
DOCUMENT NUMBER:         143:147708
TITLE:                   Methods and compositions for identifying RNA-binding
                         proteins using membrane-permeable peptide nucleic acid
                         conjugates
INVENTOR(S):             Eberwine, James; Langel, Ulo; Kilk, Kalle; Zielinski,
                         Jennifer
PATENT ASSIGNEE(S):      The Trustees of the University of Pennsylvania, USA
SOURCE:                  PCT Int. Appl., 62 pp.
                         CODEN: PIXXD2
```

```
DOCUMENT TYPE:          Patent
LANGUAGE:               English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
     WO 2005062947        A2    20050714   WO 2004-US43401        20041222
     WO 2005062947        A3    20050909
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     CA 2551094           AA    20050714   CA 2004-2551094        20041222
PRIORITY APPLN. INFO.:                     US 2003-531719P     P  20031222
                                           WO 2004-US43401     W  20041222
OTHER SOURCE(S):        MARPAT 143:147708
AB   The invention includes compns., methods and kits for the identification of
     a polypeptide that binds to a predetd.-RNA sequence.  The invention
     comprises, in part, a photoreactive moiety to aid in identification of
     such a polypeptide.  In addition, the invention features a membrane-permeable
     construct for transport of the construct across a lipid membrane,
     including a nucleic acid analog which hybridizes with an intracellular
     polynucleotide, the nucleic acid analog comprising at least one
     photoreactive moiety and a peptide moiety comprising R1-CPP-R2.  CPP is a
     cell-penetrating peptide and R1 and R2 are independently selected from the
     group consisting of a peptide, an amino acid, NH2, H, or OH.  The nucleic
     acid analog is covalently attached to one of the members selected from the
     group consisting of R1, R2, a cysteine residue within the peptide moiety,
     or a lysine residue within the peptide moiety, or a chemical bond linking the
     nucleic acid analog and the peptide moiety.  The invention claims
     sequences for cell-penetrating peptides and for peptide nucleic acids
     (PNAs) that hybridize with ankylosis mRNA.  Using a PARC (PNA annealing
     and RNA binding characterization) procedure, ankylosis mRNA binding
     proteins were identified in cortical cell cultures.  Binding of nucleolin
     with ankylosis mRNA was confirmed by fluorescence in situ immunohistochem.
     Other proteins, such as hnRNP A1, bound Ank1-Ank3 PNAs depending on
     pharmacol. stimulation.

L6   ANSWER 3 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2005:409768  CAPLUS
DOCUMENT NUMBER:        142:458079
TITLE:                  Fluorescent oligonucleotide probes with attached minor
                        groove binder for DNA detection by hybridization with
                        improved sensitivity and low background
INVENTOR(S):            Lokhov, Sergey; Lukhtanov, Eugene
PATENT ASSIGNEE(S):     Epoch Biosciences, Inc., USA
SOURCE:                 PCT Int. Appl., 89 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:          Patent
LANGUAGE:               English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
     WO 2005043127         A2     20050512    WO 2004-US37981        20041027
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004286352         A1     20050512    AU 2004-286352         20041027
     CA 2542768            AA     20050512    CA 2004-2542768        20041027
     US 2005214797         A1     20050929    US 2004-976365         20041027
     EP 1687609            A2     20060809    EP 2004-817540         20041027
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
PRIORITY APPLN. INFO.:                            US 2003-515523P    P  20031028
                                                  WO 2004-US37981    W  20041027
AB   Minor groove binder-oligonucleotide probes are provided along with methods
     for their use wherein the probes have an attached quencher and a
     fluorophore which, in an unhybridized form, exhibits very low background
     signal.

L6   ANSWER 4 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2001:277954  CAPLUS
DOCUMENT NUMBER:          134:291084
TITLE:                    UV-excitable fluorescent energy transfer dyes for
                          nucleic acid sequencing
INVENTOR(S):              Lee, Linda G.
PATENT ASSIGNEE(S):       PE Corporation, USA
SOURCE:                   U.S., 28 pp.
                          CODEN: USXXAM
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE         APPLICATION NO.        DATE
     ---------------      ----   --------     --------------------   --------
     US 6218124            B1     20010417    US 1999-385230         19990827
PRIORITY APPLN. INFO.:                        US 1999-385230         19990827
AB   A method for detecting oligonucleotides is provided and comprises forming
     a series of different sized oligonucleotides labeled with an energy
     transfer dye, separating the series of labeled oligonucleotides based on size,
     and detecting the separated labeled oligonucleotide by exposing the
     oligonucleotides to light having a wavelength between about 250 and 450
     nm, and measuring light emitted by the energy transfer dye at a wavelength
     greater than about 500 nm.  Novel energy transfer dyes which can be used
     with shorter wavelength light sources are provided.  These dyes include a
     donor dye component with an absorption maxima at a wavelength between
     about 250 to 450 nm and an acceptor dye component which is capable of
     absorbing energy emitted from the donor dye.  One of the energy transfer
     dyes has a donor dye which is a member of a class of dyes having a
     coumarin or pyrene ring structure and an acceptor dye which is capable of
     absorbing energy emitted from the donor dye, wherein the donor dye has an
     absorption maxima between about 250 and 450 nm and the acceptor dye has an
     emission maxima at a wavelength greater than about 500 nm.  The synthesis
     of several dyes containing coumarin and fluorescein groups was outlined.
REFERENCE COUNT:          34    THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
L6   ANSWER 5 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        1998:794976  CAPLUS
DOCUMENT NUMBER:         130:20606
TITLE:                   Sonodynamic therapy using an ultrasound sensitizer
                         compound
INVENTOR(S):             Alfheim, Jan Alan; Henrichs, Paul Mark; Hohenschuh,
                         Eric Paul; Johannesen, Edvin Wilhelm; Sanderson,
                         William Anthony; Snow, Robert Allen
PATENT ASSIGNEE(S):      Nycomed Imaging AS, Norway
SOURCE:                  PCT Int. Appl., 192 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
     WO 9852609           A1    19981126   WO 1998-GB1444         19980519
         W:  AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK,
             EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP,
             KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
             US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, GF, CG, CI,
             CM, GA, GN, ML, MR, NE, SN, TD, TG
     AU 9874438           A1    19981211   AU 1998-74438          19980519
     EP 979104            A1    20000216   EP 1998-921658         19980519
     EP 979104            B1    20040915
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2001525845        T2    20011211   JP 1998-550117         19980519
     AT 275971            E     20041015   AT 1998-921658         19980519
     US 6498945           B1    20021224   US 1999-435616         19991108
PRIORITY APPLN. INFO.:                     GB 1997-10049       A  19970519
                                           US 1997-48487P      P  19970603
                                           WO 1998-GB1444      W  19980519
AB   A method is provided for treatment of the human or animal body by
     sonodynamic therapy in which a sensitizer agent is administered and the
     body is exposed to ultrasound to achieve a cytopathogenic effect at a site
     therein, wherein the sensitizer agent is a physiol. tolerable substance
     which is capable of enhancing the cytopathogenic efficacy of said
     sonodynamic therapy.  Preferably, the sensitizer agent is a water-soluble
     polymer compound or a conjugate thereof.  Preparation of compds. of the
     invention is described.
REFERENCE COUNT:         9     THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6   ANSWER 6 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        1998:723794  CAPLUS
DOCUMENT NUMBER:         130:1845
TITLE:                   Physiologically tolerable chromophore-polyalkylene
                         oxide conjugate light imaging contrast
                         agents, and preparation thereof
INVENTOR(S):             Snow, Robert Allen; Henrichs, Paul Mark; Delecki,
                         Daniel Joseph; Sanderson, William Anthony; Desai,
                         Vinay Chandrakant; Bacon, Edward; Hollister, Kenneth
                         Robert; Hohenschuh, Eric Paul
PATENT ASSIGNEE(S):      Nycomed Imaging AS, Norway; Cockbain, Julian Roderick
                         Michaelson
SOURCE:                  PCT Int. Appl., 174 pp.
                         CODEN: PIXXD2
```

```
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  3
PATENT INFORMATION:

      PATENT NO.           KIND   DATE       APPLICATION NO.          DATE
      ---------------      ----   --------   --------------------     --------
      WO 9848838            A1    19981105   WO 1998-GB1244           19980428
          W:  AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK,
              EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP,
              KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US
          RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
              FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
              CM, GA, GN, ML, MR, NE, SN, TD, TG
      WO 9848845            A1    19981105   WO 1998-GB1245           19980428
          W:  AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK,
              EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP,
              KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US
          RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
              FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
              CM, GA, GN, ML, MR, NE, SN, TD, TG
      AU 9872212            A1    19981124   AU 1998-72212            19980428
      AU 9872213            A1    19981124   AU 1998-72213            19980428
      EP 979103             A1    20000216   EP 1998-919335           19980428
      EP 979103             B1    20040102
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, FI
      JP 2002504894         T2    20020212   JP 1998-546749           19980428
      AT 257014             E     20040115   AT 1998-919335           19980428
      ES 2213899            T3    20040901   ES 1998-919335           19980428
      US 6350431            B1    20020226   US 1999-429347           19991028
PRIORITY APPLN. INFO.:                       US 1997-848586        A2 19970429
                                             GB 1997-27124         A  19971222
                                             US 1998-35285         A2 19980305
                                             WO 1998-GB1244        W  19980428
                                             WO 1998-GB1245        W  19980428
AB    Physiol. tolerable light imaging contrast agent compds. are provided
      having a mol. weight in the range 500-500,000 and containing at least two
      chromophores having delocalized electron systems as well as at least one
      polyalkylene oxide (PAO) moiety having a mol. weight in the range 60-100,000.
REFERENCE COUNT:         6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6   ANSWER 7 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        1997:536959  CAPLUS
DOCUMENT NUMBER:         127:173486
TITLE:                   Polymeric fluorophores enhanced by moieties providing
                         a hydrophobic and conformationally restrictive
                         microenvironment
INVENTOR(S):             Bieniarz, Christopher; Huff, Jeffrey B.; Cornwell,
                         Michael J.; Tata Venkata, Seshagiri R.
PATENT ASSIGNEE(S):      Abbott Laboratories, USA
SOURCE:                  PCT Int. Appl., 111 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

      PATENT NO.           KIND   DATE       APPLICATION NO.          DATE
      ---------------      ----   --------   --------------------     --------
```

```
          WO 9728447          A1    19970807   WO 1997-US1429          19970130
              W:  CA, JP
              RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
          US 5994143          A     19991130   US 1996-595092          19960201
          CA 2244768          AA    19970807   CA 1997-2244768         19970130
          CA 2244768          C     20060418
          EP 1019722          A1    20000719   EP 1997-904060          19970130
          EP 1019722          B1    20030409
              R:  AT, BE, CH, DE, ES, FR, GB, IT, LI, NL
          JP 2000509412       T2    20000725   JP 1997-527793          19970130
          AT 237138           E     20030415   AT 1997-904060          19970130
          ES 2197332          T3    20040101   ES 1997-904060          19970130
     PRIORITY APPLN. INFO.:                    US 1996-595092       A  19960201
                                               WO 1997-US1429       W  19970130
     OTHER SOURCE(S):         MARPAT 127:173486
     AB   Fluorescent conjugates are disclosed that are suitable for use
          in flow cytometry and other biol. applications.  The fluorescent
          conjugates comprise an antibody having a polymeric dye bound
          thereto.  The polymeric dye is preferably enhanced by a hydrophobic and
          conformationally restrictive moiety either bound thereto or in close
          association therewith.  The hydrophobic and conformationally restrictive
          moiety is preferably derived from a cyclodextrin.  The polymeric dye
          comprises a polymeric entity having signal-generating groups, such as
          aminostyryl pyridinium dye residues attached thereto.  The fluorescent
          conjugates exhibit exceptional stability characteristics and avoid
          many of the problems of energy transfer, bio-conjugability, and solubility

     L6   ANSWER 8 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
     ACCESSION NUMBER:        1997:433759  CAPLUS
     DOCUMENT NUMBER:         127:158574
     TITLE:                   Development of the FUN-1 family of fluorescent probes
                              for vacuole labeling and viability testing of yeasts
     AUTHOR(S):               Millard, Paul J.; Roth, Bruce L.; Thi, Hong-Phuc
                              Truong; Yue, Stephen T.; Haugland, Richard p
     CORPORATE SOURCE:        Molecular Probes, Inc., Eugene, OR, 97402, USA
     SOURCE:                  Applied and Environmental Microbiology (1997), 63(7),
                              2897-2905
                              CODEN: AEMIDF; ISSN: 0099-2240
     PUBLISHER:               American Society for Microbiology
     DOCUMENT TYPE:           Journal
     LANGUAGE:                English
     AB   A new family of fluorescent probes has been developed for assessing the
          viability and metabolic activity of yeasts.  This class of halogenated
          unsym. cyanine dyes is exemplified by the FUN-1
          [2-chloro-4-(2,3-dihydro-3-methyl-(benzo-1,3-thiazol-2-yl)-methylidene)-1-
          phenylquinolinium iodide] stain, a membrane-permeant nucleic acid-binding
          dye that has been found to give rise to cylindrical intravacuolar
          structures (CIVS) in Saccharomyces cerevisiae.  Biochem. processing of the
          dye by active yeasts yielded CIVS that were markedly red shifted in
          fluorescence emission and therefore spectrally distinct from the nucleic
          acid-bound form of the dye.  The formation of CIVS occurred under both
          aerobic and anaerobic conditions and was highly temperature dependent.
          Treatment of yeasts with the nonmetabolizable glucose analog
          2-deoxy-D-glucose reduced cellular ATP levels .apprx.6-fold and completely
          inhibited CIVS formation.  Under aerobic conditions, the formation of CIVS
          was abrogated by the cytochrome oxidase inhibitors azide and
          cyanide; however, the H+ transport uncoupler carbonyl cyanide
          m-chlorophenylhydrazone inhibited CIVS formation under both aerobic and
          anaerobic conditions.  Depletion of cellular thiols, including
          glutathione, with millimolar concns. of N-ethylmaleimide, iodoacetamide,
          or allyl alc. completely inhibited CIVS production  Marked reduction in the
          formation of CIVS by ethacrynic acid and sulfobromophthalein, inhibitors
          of glutathione S-transferase, suggested that dye processing can involve
     enzyme-mediated formation of glutathione conjugates.  The
     conversion of FUN-1 by S. cerevisiae was studied quant. by using several
     techniques, including fluorometry, flow cytometry, and wide-field and
     confocal laser scanning fluorescence microscopy.
REFERENCE COUNT:         32    THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> cyanine and bombesin
CYANINE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s cyanine and bombesin
         15234 CYANINE
          1353 CYANINES
         15631 CYANINE
                 (CYANINE OR CYANINES)
          4216 BOMBESIN
            22 BOMBESINS
          4221 BOMBESIN
                 (BOMBESIN OR BOMBESINS)
L7          11 CYANINE AND BOMBESIN

=> s l7 not l5 l6
MISSING OPERATOR L5 L6
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l7 not l5
L8           9 L7 NOT L5

=> s l9 not l6
L9 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l8 not l6
L9           9 L8 NOT L6

=> d l9 ibib abs hitstr tot

L9   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2005:1333901  CAPLUS
DOCUMENT NUMBER:         144:57368
TITLE:                   Receptor-avid exogenous optical contrast and
                         therapeutic agents
INVENTOR(S):             Achilefu, Samuel I.; Rajagopalan, Raghavan; Dorshow,
                         Richard B.; Bugaj, Joseph E.; Periasamy, Muthunadar P.
PATENT ASSIGNEE(S):      USA
SOURCE:                  U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S.
                         Ser. No. 800,531.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  6
PATENT INFORMATION:

     PATENT NO.          KIND    DATE          APPLICATION NO.          DATE
     ---------------     ----    --------      --------------------     --------
     US 2005281741        A1     20051222      US 2005-75792            20050309
     US 6395357           B1     20020528      US 2000-484322           20000118
     US 2002156117          A1     20021024    US 2001-864011          20010523
     US 6706254             B2     20040316
     US 2004241095          A1     20041202    US 2004-800531          20040315
     US 2005271592          A1     20051208    US 2005-146377          20050606
PRIORITY APPLN. INFO.:                         US 2000-484322       A2 20000118
                                               US 2001-864011       A2 20010523
                                               US 2004-800531       A2 20040315
                                               US 2005-75792        A3 20050309
OTHER SOURCE(S):          MARPAT 144:57368
AB   Cyanine and Indocyanine dye compds. and bioconjugates are
     disclosed.  The present invention includes several cyanine and
     indocyanine dyes, including bioconjugates of the same, with a variety of
     bis- and tetrakis (carboxylic acid) homologues.  The compds. of the
     invention may be conjugated to bioactive peptides, carbohydrates,
     hormones, drugs, or other bioactive agents.  The small size of compds. of
     the invention allows favorable delivery to tumor cells as compared to
     larger mol. weight imaging agents.  Further, use of a biocompatible organic
     solvent such as dimethylsulfoxide may be said to assist in maintaining the
     fluorescence of compds. of the invention.  The compds. and bioconjugates
     herein disclosed are useful in a variety of medical applications
     including, but not limited to, diagnostic imaging and therapy, endoscopic
     applications for the detection of tumors and other abnormalities,
     localized therapy, photoacoustic tumor imaging, detection and therapy, and
     sonofluorescence tumor imaging, detection and therapy.

L9   ANSWER 2 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:589014  CAPLUS
DOCUMENT NUMBER:          141:136291
TITLE:                    Tumor-targeted optical contrast agents, indocyanine
                          dye compounds, compositions, and performing a
                          diagnostic procedure
INVENTOR(S):              Achilefu, Samuel I.; Rajagopalan, Raghavan; Dorshow,
                          Richard B.; Bugaj, Joseph E.; Periasamy, Muthunadar P.
PATENT ASSIGNEE(S):       Mallinckrodt Inc., USA
SOURCE:                   U.S. Pat. Appl. Publ., 32 pp., Cont.-in-part of U. S.
                          Ser. No. 863,971.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.             KIND   DATE        APPLICATION NO.         DATE
     ---------------        ----   --------    --------------------    --------
     US 2004141920           A1    20040722    US 2003-654033          20030903
     JP 2003520215           T2    20030702    JP 2001-552798          20010117
     US 2002044909           A1    20020418    US 2001-863971          20010523
     US 6641798              B2    20031104
PRIORITY APPLN. INFO.:                         US 2000-484320       A2 20000118
                                               US 2001-863971       A2 20010523
                                               WO 2001-US1467       W  20010117
OTHER SOURCE(S):          MARPAT 141:136291
AB   Cyanine dye bioconjugates are useful for diagnostic imaging and
     therapy.  The conjugates include several cyanine dyes with a
     variety of bis- and tetrakis (carboxylic acid) homologs.  The compds. may
     be conjugated to bioactive peptides, carbohydrates, hormones, drugs, or
     other bioactive agents.  The small size of the compds. allows more
     favorable delivery to tumor cells as compared to larger mol. weight imaging
     agents.  The various dyes are useful at 350-1300 nm, the exact range being
     dependent upon the particular dye.  The use of DMSO helps to maintain the
     fluorescence of the compds.  The inventive compds. are useful for
     diagnostic imaging and therapy, in endoscopic applications for the
     detection of tumors and other abnormalities, for localized therapy, for
     photoacoustic tumor imaging, detection and therapy, and for
     sonofluoresence tumor imaging, detection and therapy.

L9   ANSWER 3 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:402754  CAPLUS
DOCUMENT NUMBER:          140:388251
TITLE:                    Versatile hydrophilic cyanine dyes and their
                          peptide conjugates for diagnostic imaging and therapy
INVENTOR(S):              Achilefu, Samuel I.; Rajagopalan, Raghavan; Dorshow,
                          Richard B.; Bugaj, Joseph E.
PATENT ASSIGNEE(S):       Mallinckrodt, Inc., USA
SOURCE:                   U.S. Pat. Appl. Publ., 31 pp., Cont.-in-part of U.S.
                          6,183,726.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
     US 2003165432        A1    20030904    US 2001-757333          20010109
     US 6939532           B2    20050906
     US 6183726           B1    20010206    US 2000-484321          20000118
     EP 1250095           A1    20010223    EP 2001-906573          20010117
     EP 1250095           B1    20041013
         R:  AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
             NL, PT, SE, TR
     WO 2001052746        A1    20010726    WO 2001-US1471          20010117
     WO 2001052746        C2    20021031
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
             IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
             GW, ML, MR, NE, SN, TD, TG
     JP 2003535041        T2    20031125    JP 2001-552801          20010117
     AT 279147            E     20041015    AT 2001-906573          20010117
     ES 2231445           T3    20050516    ES 2001-1906573         20010117
     US 2005201939        A1    20050915    US 2005-126137          20050510
PRIORITY APPLN. INFO.:                      US 2000-484321      A2  20000118
                                            US 2001-757333      A   20010109
                                            WO 2001-US1471      W   20010117
OTHER SOURCE(S):          MARPAT 140:388251
GI
```



I

AB Dye-peptide conjugates useful for diagnostic imaging and therapy are disclosed. The dye-peptide conjugates include several cyanine dyes with a variety of bis- and tetrakis(carboxylic acid) homologs. The small size of the compds. allows more favorable delivery to tumor cells as compared to larger mol. weight imaging agents. The various dyes are useful over the range of 350-1300 nm, the exact range being dependent upon the particular dye. Use of dimethylsulfoxide helps to maintain the fluorescence of the compds. The mols. of the invention are useful for diagnostic imaging and therapy, in endoscopic applications for the detection of tumors and other abnormalities and for localized therapy, for photoacoustic tumor imaging, detection and therapy, and for sonofluorescence tumor imaging, detection and therapy. Thus, the bis(ethylcarboxymethyl)indocyanine dye I (R1,R2=fused Ph, A=CH2, n=1, and R=R'=CO2H) is conjugated with Octreolate and the monoOctreotate-Bisethylcarboxymethylindocyanine dye (Cytate 1) used for imaging of rat pancreatic acinar carcinoma.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:633039 CAPLUS
DOCUMENT NUMBER: 139:175958
TITLE: Dye-bioconjugates for simultaneous optical diagnostic and therapeutic applications
INVENTOR(S): Achilefu, Samuel; Rajagopalan, Raghavan; Dorshow, Richard B.; Bugaj, Joseph E.
PATENT ASSIGNEE(S): Mallinckrodt Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```
    PATENT NO.          KIND    DATE        APPLICATION NO.         DATE
    ---------------     ----    --------    --------------------    --------
    US 2003152577        A1     20030814    US 2002-71779           20020207
    WO 2003065888        A1     20030814    WO 2003-US2901          20030131
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    AU 2003208908        A1     20030902    AU 2003-208908          20030131
    JP 2006503798        T2     20060202    JP 2003-565320          20030131
PRIORITY APPLN. INFO.:                      US 2002-71779        A  20020207
                                            WO 2003-US2901       W  20030131
```

OTHER SOURCE(S): MARPAT 139:175958

AB Novel tumor specific phototherapeutic and photodiagnostic agents are disclosed. The compds. consist of a carbocyanine dye for visualization, photosensitizer for photodynamic treatment, and tumor receptor-avid peptide for site-specific delivery of the probe and phototoxic agent to diseased tissues. A combination of these elements takes full advantage of the unique and efficient properties of each component for an effective patient care management. Several examples are given of tumor imaging and photodynamic therapy using the dye bioconjugates.

```
L9   ANSWER 5 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2003:590578  CAPLUS
DOCUMENT NUMBER:          139:138722
TITLE:                    Hydrophilic cyanine dye conjugates for
                          diagnostic imaging and therapy
INVENTOR(S):              Achilefu, Samuel I.; Rajagopalan, Raghavan; Dorshow,
                          Richard B.; Bugaj, Joseph E.
PATENT ASSIGNEE(S):       Mallinckrodt Inc., USA
SOURCE:                   U.S. Pat. Appl. Publ., 31 pp., Cont.-in-part of U.S.
                          Ser. No. 484,319.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
     US 2003143159        A1    20030731   US 2001-757332         20010109
     US 7011817           B2    20060314
     US 6180086           B1    20010130   US 2000-484319         20000118
     WO 2001052744        A1    20010726   WO 2001-US1468         20010117
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
             IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
             GW, ML, MR, NE, SN, TD, TG
     EP 1250091           A1    20021023   EP 2001-904882         20010117
         R:  AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
             NL, PT, SE, TR
     JP 2003529632        T2    20031007   JP 2001-552799         20010117
     AU 2001032818        A5    20010731   AU 2001-32818          20010731
PRIORITY APPLN. INFO.:                     US 2000-484319      A2 20000118
                                           US 2001-757332      A  20010109
                                           WO 2001-US1468      W  20010117
OTHER SOURCE(S):          MARPAT 139:138722
AB   Cyanine dye bioconjugates useful for diagnostic imaging and
     therapy are disclosed.  The conjugates include several cyanine
     dyes with a variety of bis- and tetrakis (carboxylic acid) homologues.
     The compds. may be conjugated to bioactive peptides, carbohydrates,
     hormones, drugs, or other bioactive agents.  The small size of the compds.
     allows more favorable delivery to tumor cells as compared to larger mol.
     weight imaging agents.  The various dyes are useful over the range of
     350-1300 nm, the exact range being dependent upon the particular dye.  Use
     of dimethylsulfoxide helps to maintain the fluorescence of the compds.
     The inventive compds. are useful for diagnostic imaging and therapy, in
     endoscopic applications for the detection of tumors and other
     abnormalities, for localized therapy, for photoacoustic tumor imaging,
     detection and therapy, and for sonofluorescence tumor imaging, detection
     and therapy.
REFERENCE COUNT:          28    THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9   ANSWER 6 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2003:117543  CAPLUS
DOCUMENT NUMBER:          138:149628
TITLE:                    Internal image antibodies for optical imaging and
```

```
                           therapy
INVENTOR(S):               Rajagopalan, Raghavan; Bugaj, Joseph E.; Achilefu,
                           Samuel I.; Dorshow, Richard B.
PATENT ASSIGNEE(S):        Mallinckrodt Inc., USA
SOURCE:                    PCT Int. Appl., 50 pp.
                           CODEN: PIXXD2
DOCUMENT TYPE:             Patent
LANGUAGE:                  English
FAMILY ACC. NUM. COUNT:    1
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.         DATE
     ---------------       ----   --------    --------------------    --------
     WO 2003011106          A2    20030213    WO 2002-US22755         20020718
     WO 2003011106          A3    20041202
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     US 2003031627          A1    20030213    US 2001-919243          20010731
     EP 1501524             A2    20050202    EP 2002-756510          20020718
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     JP 2005508880          T2    20050407    JP 2003-516346          20020718
     US 2004151667          A1    20040805    US 2004-761634          20040121
PRIORITY APPLN. INFO.:                        US 2001-919243      A   20010731
                                              WO 2002-US22755     W   20020718
OTHER SOURCE(S):           MARPAT 138:149628
AB   Compns. and methods using internal image antibodies for photodiagnosis
     and/or phototherapy are claimed.  The internal image antibodies are
     conjugated with a photoactive mol. such as a dye or photosensitizer, to
     target specific regions, such as biol. receptors.  The photoactive mols.
     are then activated for diagnosis or therapy.  Advantageously, the internal
     image antibody is specific for a biol. receptor, but does not require
     isolation of the receptor to prepare the antibody, and provides the desired
     specificity for therapy.

L9   ANSWER 7 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:          2002:294120  CAPLUS
DOCUMENT NUMBER:           136:306089
TITLE:                     Tumor-targeted optical contrast agents
INVENTOR(S):               Achilefu, Samuel I.; Rajagopalan, Raghavan; Dorshow,
                           Richard B.; Bugaj, Joseph E.
PATENT ASSIGNEE(S):        Mallinckrodt Inc., USA
SOURCE:                    U.S. Pat. Appl. Publ., 31 pp., Cont.-in-part of U.S.
                           Ser. No. 484,320.
                           CODEN: USXXCO
DOCUMENT TYPE:             Patent
LANGUAGE:                  English
FAMILY ACC. NUM. COUNT:    2
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.         DATE
     ---------------       ----   --------    --------------------    --------
     US 2002044909          A1    20020418    US 2001-863971          20010523
     US 6641798             B2    20031104
     JP 2003520215       T2     20030702    JP 2001-552798         20010117
     US 2004141920       A1     20040722    US 2003-654033         20030903
PRIORITY APPLN. INFO.:                      US 2000-484320      A2 20000118
                                            WO 2001-US1467      W  20010117
                                            US 2001-863971      A2 20010523
OTHER SOURCE(S):         MARPAT 136:306089
AB   Cyanine dye bioconjugates useful for diagnostic imaging and
     therapy are disclosed.  The conjugates include several cyanine
     dyes with a variety of bis- and tetrakis (carboxylic acid) homologs.  The
     compds. may be conjugated to bioactive peptides, carbohydrates, hormones,
     drugs, or other bioactive agents.  The small size of the compds. allows
     more favorable delivery to tumor cells as compared to larger mol. weight
     imaging agents.  The various dyes are useful over the range of 350 to
     1,300 nm, the exact range being dependent upon the particular dye.  The
     use of dimethylsulfoxide helps to maintain the fluorescence of the compds.
     The inventive compds. are useful for diagnostic imaging and therapy, in
     endoscopic applications for the detection of tumors and other
     abnormalities, for localized therapy, for photoacoustic tumor imaging,
     detection and therapy, and for sonofluorescence tumor imaging, detection
     and therapy.

L9   ANSWER 8 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2002:264159  CAPLUS
DOCUMENT NUMBER:         137:33520
TITLE:                   Synthesis, In Vitro Receptor Binding, and In Vivo
                         Evaluation of Fluorescein and Carbocyanine
                         Peptide-Based Optical Contrast Agents
AUTHOR(S):               Achilefu, Samuel; Jimenez, Hermo N.; Dorshow, Richard
                         B.; Bugaj, Joseph E.; Webb, Elizabeth G.; Wilhelm, R.
                         Randy; Rajagopalan, Raghavan; Johler, Jill; Erion,
                         Jack L.
CORPORATE SOURCE:        Mallinckrodt Institute of Radiology, Washington
                         University School of Medicine, St. Louis, MO, 63110,
                         USA
SOURCE:                  Journal of Medicinal Chemistry (2002), 45(10),
                         2003-2015
                         CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER:               American Chemical Society
DOCUMENT TYPE:           Journal
LANGUAGE:                English
OTHER SOURCE(S):         CASREACT 137:33520
AB   Site-specific delivery of drugs and contrast agents to tumors protects
     normal tissues from the cytotoxic effects of drugs and enhances the
     contrast between normal and pathol. tissues.  One approach to achieve
     selectivity is to target overexpressed receptors on the membranes of tumor
     cells and to visualize the tumors by a noninvasive optical imaging method.
     Accordingly, the authors conjugated fluorescein and carbocyanine dyes to
     somatostatin and bombesin receptor-avid peptides and examined
     their receptor binding affinities.  The authors also prepared potential dual
     imaging probes consisting of a bioactive peptide for tumor targeting, a
     biocompatible dye for optical imaging, and a radioactive or paramagnetic
     metal chelator for scintigraphic or magnetic resonance imaging of tumors.
     Using these approaches, the resulting carbocyanine derivs. of somatostatin
     and bombesin analogs retained high binding for their resp.
     receptors.  Further evaluation of representative mols. in rats bearing
     somatostatin- and bombesin-pos. tumors showed selective uptake
     of the agents by the tumor cells.  Unlike carbocyanine derivs., the
     receptor binding of fluorescein-somatostatin peptide conjugates was highly
     sensitive to the type of linker and the site of fluorescein attachment on
     the nonreceptor binding region of the peptide.  In general, the presence
     of flexible linkers disrupted binding affinity, possibly due to the
     interaction of the linker's thiourea group with the peptide's cyclic
     disulfide bond.  While the receptor binding affinity of the dual probes
```

was not dependent on the type of chelating group examined, it was affected by the relative positions of fluorescein and chelator on the lysine linker. For somatostatin compds., best results were obtained when the chelator was on the α-amino lysine linker and fluorescein was on the ε-amino group. In contrast, conjugation of the chelator to ε- and fluorescein to the α-amino lysine linker of bombesin peptides resulted in high receptor binding. These findings indicate that, despite their small size, conjugation of dyes to truncated somatostatin and bombesin peptide analogs results in promising diagnostic agents that retain high receptor binding activity in vitro. The results further show that these contrast agents can selectively and specifically localize in receptor-pos. tumors in rat models.

```
REFERENCE COUNT:         48     THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9   ANSWER 9 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2000:842014  CAPLUS
DOCUMENT NUMBER:         134:21520
TITLE:                   Novel cyanine and indocyanine dye
                         bioconjugates for biomedical applications
INVENTOR(S):             Achilefu, Samuel; Dorshow, Richard Bradley; Bugaj,
                         Joseph Edward; Rajagopalan, Raghavan
PATENT ASSIGNEE(S):      Mallinckrodt Inc., USA
SOURCE:                  PCT Int. Appl., 38 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND    DATE        APPLICATION NO.        DATE
     ---------------     ----    --------    --------------------   -------- ✓
     WO 2000071162        A2     20001130    WO 2000-US11060        20000426
     WO 2000071162        A3     20010705
         W:  AU, CA, JP
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
     US 6217848           B1     20010417    US 1999-325769         19990604
     CA 2373475           AA     20001130    CA 2000-2373475        20000426
     EP 1178830           A2     20020213    EP 2000-926343         20000426
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2003500367        T2     20030107    JP 2000-619463         20000426
PRIORITY APPLN. INFO.:                       US 1999-135060P     P  19990520
                                             US 1999-325769      A  19990604
                                             WO 2000-US11060     W  20000426
OTHER SOURCE(S):         MARPAT 134:21520
```

AB Dye-peptide conjugates useful for diagnostic imaging and therapy are disclosed. The dye-peptide conjugates include several cyanine dyes with a variety of bis- and tetrakis(carboxylic acid) homologs. The small size of the compds. allows more favorable delivery to tumor cells as compared to larger mol. weight imaging agents. The various dyes are useful over the range of 350-1300 nm, the exact range being dependent upon the particular dye. Use of dimethylsulfoxide helps to maintain the fluorescence of the compds. The mols. of the invention are useful for diagnostic imaging and therapy, in endoscopic applications for the detection of tumors and other abnormalities and for localized therapy, for photoacoustic tumor imaging, detection and therapy, and for sonofluorescence tumor imaging, detection and therapy. For example, monooctreotate-bisethylcarboxymethyl indocyanine dye (Cytate 1) was prepared (yield of 80%) and evaluated in the CA20948 Lewis rat model of pancreatic acinar carcinoma. Using the CCD camera, strong localization of this dye

```
     was observed in the tumor at 90 min post injection.  At 19 h post injection
     the animal was again imaged and tumor visualization was easily observed
     showing specificity of this agent for somatostatin receptors present in
     this tumor line.


=> log y
COST IN U.S. DOLLARS                             SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   87.97      88.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -15.00     -15.00

STN INTERNATIONAL LOGOFF AT 12:59:41 ON 12 SEP 2006
```